Statistik Asas
| CIK | 1863127 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tyra Biosciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 14, 2025 |
Non-Employee Director Compensation Program, amended and restated effective May 29, 2025 Exhibit 10.1 Tyra Biosciences, Inc. Non-Employee Director Compensation Program (Amended and Restated Effective May 29, 2025) Non-employee members of the board of directors (the “Board”) of Tyra Biosciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in t |
|
| August 14, 2025 |
Exhibit 99.1 Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights - Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3 million at Q2 2025; runway through at least 2027 - CARLSBAD, Calif., August 14, 2025 – Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage b |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 14, 2025 |
Tyra Biosciences, Inc. 2656 State Street Carlsbad, CA 92008 Tyra Biosciences, Inc. 2656 State Street Carlsbad, CA 92008 May 14, 2025 VIA EDGAR Jason Drory Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Tyra Biosciences, Inc. Registration Statement on Form S-3 File No. 333-287086 To the addressee set forth above: Pursuant to Rule 461 of Regulation C of the General |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 8, 2025 |
Exhibit 4.6 TYRA BIOSCIENCES, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establishm |
|
| May 8, 2025 |
Sales Agreement, dated May 8, 2025, by and between the Registrant and TD Securities (USA) LLC Exhibit 1.2 TYRA BIOSCIENCES, INC. $150,000,000 COMMON STOCK SALES AGREEMENT May 8, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Tyra Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows, it being understood that all references in this Agreement t |
|
| May 8, 2025 |
As filed with the Securities and Exchange Commission on May 8, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 8, 2025 Registration No. |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 8, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Registration Statement on Form S-3 (Form Type) Tyra Biosciences, Inc. |
|
| May 8, 2025 |
Exhibit 99.1 Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights - BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment - - Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC) - - Cash, cash equivalents, and marketable securities of $318.9 million at Q1 2025; runway through at least 2027 - CARLSBAD, Calif., |
|
| April 18, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| April 18, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40800 TYRA BIOSCIENCE |
|
| March 27, 2025 |
Exhibit 99.1 Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights - Three INDs cleared by US FDA for TYRA’s proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC), BEACH301 for pediatric achondroplasia (ACH) and SURF301 for metastatic urothelial c |
|
| March 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 27, 2025 |
Insider Trading Compliance Policy and Procedures Exhibit 19.1 Tyra Biosciences, Inc. Insider Trading Compliance Policy and Procedures Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this information to others who may trade. Violat |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 6, 2024 |
TYRA / Tyra Biosciences, Inc. / Boxer Capital Management, LLC Activist Investment SC 13D/A 1 ff420987613da6-tyra.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 6)* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 90240B106 (CU |
|
| November 19, 2024 |
EX-7 2 ff4142386ex7-tyra.htm STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of November 8, 2024 (the “Effective Date”), by and among RA Capital Healthcare Fund, L.P. a Delaware limited partnership (the “Purchaser”), on the one hand, and Boxer Capital, LLC, a Delaware limited liability company (“Seller”), on the other hand (each a “Party”). The Seller desires to |
|
| November 19, 2024 |
TYRA / Tyra Biosciences, Inc. / Boxer Capital Management, LLC Activist Investment SC 13D/A 1 ff414238613da5-tyra.htm UNITED STATES SECURITIES AND EXCHANedgGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 5)* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 90240B106 |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga207422tyra11142024.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Tyra Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par |
|
| November 14, 2024 |
EX-99.A 2 tm2427660d299-a.htm EXHIBIT 99.A Exhibit 99.A EXHIBIT A JOINT FILING STATEMENT We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Tyra Biosciences, Inc. is filed on behalf of each of us. Dated: November 14, 2024 Nextech VI Oncology SCSp By: Nextech VI GP S.à r.l. its General Partner By: /s/ Ian Char |
|
| November 14, 2024 |
TYRA / Tyra Biosciences, Inc. / NEXTECH VI ONCOLOGY SCSP - SC 13G/A Passive Investment SC 13G/A 1 tm2427660d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 90240B106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| November 13, 2024 |
EX-7 3 tm2428367d1ex7.htm EXHIBIT 7 Exhibit 7 STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of November 8, 2024 (the “Effective Date”), by and among RA Capital Healthcare Fund, L.P. a Delaware limited partnership (the “Purchaser”), on the one hand, and Boxer Capital, LLC, a Delaware limited liability company (“Seller”), on the other hand (each a “Party”). The |
|
| November 13, 2024 |
EX-1 2 tm2428367d1ex1.htm EXHIBIT 1 CUSIP No. 90240B106 EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 13, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Sec |
|
| November 13, 2024 |
TYRA / Tyra Biosciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 90240B106 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617 |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 7, 2024 |
Employment Agreement, dated September 9, 2024, between the Registrant and Douglas Warner, M.D. Exhibit 10.2 TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is effective as of September 9, 2024 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Douglas Warner, M.D. (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and not otherwise defined shall have those m |
|
| November 7, 2024 |
Transition Agreement, dated August 3, 2024, between the Registrant and Hiroomi Tada, M.D., Ph.D. Exhibit 10.1 TYRA BIOSCIENCES, INC. TRANSITION AGREEMENT This Transition Agreement (the “Agreement”) is entered into effective as of August 3, 2024 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Hiroomi Tada, M.D., Ph.D. (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and not otherwise defined sha |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 7, 2024 |
Exhibit 99.1 Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - - Cash, cash equivalents, a |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 25, 2024 |
Interim clinical proof-of-concept with TYRA-300 in mUC (SURF301) October 25, 2024 Exhibit 99. |
|
| October 22, 2024 |
TYRA / Tyra Biosciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2426636-1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 90240B106 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 0 |
|
| October 22, 2024 |
TYRA / Tyra Biosciences, Inc. / Boxer Capital Management, LLC Activist Investment SC 13D/A 1 ff402517513da4-tyra.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 4)* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 90240B106 (CU |
|
| October 18, 2024 |
Exhibit 4.1 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 15, 2024 |
TYRA / Tyra Biosciences, Inc. / Boxer Capital, LLC Activist Investment SC 13D/A 1 ff399731213da-tyraboxcap.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 3)* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90240B106 |
|
| October 15, 2024 |
TYRA / Tyra Biosciences, Inc. / Boxer Asset Management Inc. Activist Investment SC 13D/A 1 ff399115613da3-tyra.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 3)* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 90240B106 (CU |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2024 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 7, 2024 |
Exhibit 99.1 Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights - SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Reported preclinical proof-of-concept with TYRA-300 in HCH, demonstrating increases in long bone length and binding against the HCH altered protein - -IND cleared for TYRA-430, an FGFR4/3 biased inhibitor for HCC - - Announced Chief Me |
|
| August 7, 2024 |
l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 31, 2024 |
Certificate of Amendment of Amended and Restated Certificate of Incorporation, dated May 29, 2024 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TYRA BIOSCIENCES, INC. Tyra Biosciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The Corporation originally filed its Certificate of Incorporation on August 2, 2018. 2. This Ce |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 9, 2024 |
Non-Employee Director Compensation Program, amended and restated effective May 1, 2024 Exhibit 10.3 Tyra Biosciences, Inc. Non-Employee Director Compensation Program (Amended and Restated Effective May 1, 2024) Non-employee members of the board of directors (the “Board”) of Tyra Biosciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in th |
|
| May 9, 2024 |
l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 9, 2024 |
Exhibit 99.1 Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights - TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Cash, cash equivalents, and marketable securities of $382.5 million at Q1 2024 - - Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. appointed to TYRA Board of Directors - CARLSBAD |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2024 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 18, 2024 |
Tyra Biosciences, Inc. 2656 State Street Carlsbad, CA 92008 Tyra Biosciences, Inc. 2656 State Street Carlsbad, CA 92008 April 18, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Tyra Biosciences, Inc. Registration Statement on Form S-3 File No. 333-278068 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the |
|
| April 18, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 5, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| March 19, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 19, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Tyra Biosciences, Inc. |
|
| March 19, 2024 |
Exhibit 99.1 Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights - Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 - - TYRA-300 Phase 2 ACH IND submission on track for 2H 2024 - - Initiated SURF201 Phase 1 study and dosed first patient with TYRA-200 - - Strengthened balance sheet with approximately $200 million PIPE |
|
| March 19, 2024 |
Exhibit 10.23 THIRD AMENDMENT TO LEASE This Third Amendment to Lease (this “Amendment”) is made and entered into as of March 18, 2024, by and between Fabric 2676 State Street, LLC, a California limited liability company (“Lessor”), and TYRA Biosciences, Inc., a Delaware corporation (“Lessee”). RECITALS A. Lessor and Lessee are parties to that certain AIR Standard Industrial/Commercial Multi-Tenant |
|
| March 19, 2024 |
As filed with the Securities and Exchange Commission on March 19, 2024 As filed with the Securities and Exchange Commission on March 19, 2024 Registration No. |
|
| March 19, 2024 |
As filed with the Securities and Exchange Commission on March 19, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on March 19, 2024 Registration No. |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40800 TYRA BIOSCIENCE |
|
| March 19, 2024 |
Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 TYRA BIOSCIENCES, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Tyra Biosciences, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Poli |
|
| March 19, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Tyra Biosciences, Inc. |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Tyra Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 90240B106 (CUSIP Number) |
|
| February 9, 2024 |
TYRA / Tyra Biosciences, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 TYRA BIOSCIENCES INC COMMON STOCK Cusip #90240B106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #90240B106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,768,497 Item 6: 0 Item 7: 2,768,696 Item 8: 0 Item 9 |
|
| February 8, 2024 |
TYRA / Tyra Biosciences, Inc. / Boxer Capital, LLC Activist Investment SC 13D/A 1 ff300290813da-tyra.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (RULE 13D - 101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. 2)* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 90240B106 (CUS |
|
| February 6, 2024 |
TYRA / Tyra Biosciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment 1)* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 90240B106 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, A |
|
| February 5, 2024 |
Exhibit 10.1 TYRA BIOSCIENCES, INC. SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of February 1, 2024 (the “Effective Date”), by and between TYRA BIOSCIENCES, INC., a Delaware corporation (the “Company”), and each of the purchasers whose names and addresses are set forth on Schedule A hereto (each, a “Purchaser” and, collectively, the “Purchasers”). |
|
| February 5, 2024 |
Exhibit 4.1 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2024 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40800 83-1476348 (State or other jurisdiction of incorporation) (Commission |
|
| February 5, 2024 |
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing Exhibit 99.1 Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing CARLSBAD, Calif., February 2, 2024 – Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that it has entered into a securities p |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2024 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40800 83-1476348 (State or other jurisdiction of incorporation) (Commission |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2023 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40800 83-1476348 (State or other jurisdiction of incorporation) (Commissio |
|
| November 7, 2023 |
Non-Employee Director Compensation Program, amended and restated effective August 1, 2023 Exhibit 10.1 Tyra Biosciences, Inc. Non-Employee Director Compensation Program (Amended and Restated Effective August 1, 2023) Non-employee members of the board of directors (the “Board”) of Tyra Biosciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in |
|
| November 7, 2023 |
l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 7, 2023 |
Exhibit 99.1 Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights - Enrollment and dose escalation ongoing in SURF301 Phase 1/2 oncology - - Presented additional preclinical data on TYRA-300 in achondroplasia at ASBMR and ASHG - - First patient to be dosed in TYRA-200 Phase 1 by YE 2023 - - Strong cash position of $215.7 million as of Q3 2023 - CARLSBAD, Calif., November 7, |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2023 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40800 83-1476348 (State or other jurisdiction of incorporation) (Commission |
|
| October 26, 2023 |
Exhibit 3.2 Amended and Restated Bylaws of Tyra Biosciences, Inc. (a Delaware corporation) as of October 26, 2023 Table of Contents Page ArticleARTICLE I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 ArticleARTICLE II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought beforeBefore a Meeting. 22 2. |
|
| October 26, 2023 |
Amended and Restated Bylaws, effective as of October 26, 2023 Exhibit 3.1 Amended and Restated Bylaws of Tyra Biosciences, Inc. (a Delaware corporation) as of October 26, 2023 Table of Contents Page ARTICLE I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought Before a Meeting 2 2.5 Notice of Nomination |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 10, 2023 |
Exhibit 99.1 Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights -Orphan Drug Designation granted to TYRA-300 for achondroplasia- - SURF301 Phase 1/2 oncology study remains on target; enrollment ongoing in Part B - -TYRA-200 Phase 1 study on track; first patient to be dosed in 2H 2023- - Strong cash position of $232.4 million as of Q2 2023- CARLSBAD, Calif., August 10, 20 |
|
| August 10, 2023 |
l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| June 2, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2023 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40800 83-1476348 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 4, 2023 |
l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 4, 2023 |
Exhibit 99.1 Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights -SURF301 Phase 1/2 oncology study continues to advance- - Expanded TYRA-300 clinical development into achondroplasia- -IND for TYRA-200 cleared with Phase 1 study on track for 2H 2023- -Strong cash position of $241.7 million as of Q1 2023- CARLSBAD, Calif., May 4, 2023 – Tyra Biosciences, Inc. (Nasdaq: TYRA), |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2023 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 17, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 22, 2023 |
Exhibit 10.19 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (this “Amendment”) is made and entered into as of December 20, 2022, by and between Fabric 2656 State, LLC, a California limited liability company (“Lessor”), and TYRA Biosciences, Inc., a Delaware corporation (“Lessee”). RECITALS A. Lessor and Lessee are parties to that certain AIR Standard Industrial/Commercial Multi-Lessee L |
|
| March 22, 2023 |
Exhibit 99.1 Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights -Initiated patient dosing with TYRA-300 in SURF301 oncology study- -Expanded pipeline beyond oncology into genetically defined conditions with TYRA-300 for achondroplasia- -Cleared IND for TYRA-200 Phase 1 study; first patient dosed expected in 2H 2023 - -Well-capitalized with cash and cash equ |
|
| March 22, 2023 |
Exhibit 10.22 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (this “Amendment”) is made and entered into as of January 6, 2023, by and between Fabric 2676 State Street, LLC, a California limited liability company (“Lessor”), and TYRA Biosciences, Inc., a Delaware corporation (“Lessee”). RECITALS A. Lessor and Lessee are parties to that certain AIR Standard Industrial/Commercial Multi-Ten |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40800 TYRA BIOSCIENCE |
|
| March 22, 2023 |
Employment Letter Agreement, dated December 31, 2022, by and between Alan Fuhrman and the Registrant Exhibit 10.14 TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is effective as of December 31, 2022 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Alan Fuhrman (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and not otherwise defined shall have those meanings |
|
| March 22, 2023 |
Consulting Agreement, dated January 1, 2023, by and between Esther van den Boom and the Registrant Exhibit 10.16 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is effective as of January 1, 2023 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”), and Esther van den Boom (“Advisor”). RECITALS Whereas, Advisor has been employed by the Company as its Chief Financial Officer; Whereas, Advisor and the Company are parties to that ce |
|
| March 22, 2023 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TYRA BIOSCIENCES, INC. Tyra Biosciences, Inc. (the "Corporation"), a corporation organized and existing under the General Corporation Law of the State of Delaware (the "DGCL"), does hereby certify as follows: 1. The name of the Corporation is Tyra Biosciences, Inc. The Corporation was incorporated under the name Tyra Biosciences, Inc |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 22, 2023 |
Tyra Biosciences, Inc. Annual Bonus Plan Exhibit 10.5 TYRA BIOSCIENCES, INC. ANNUAL BONUS PLAN 1. PURPOSE This Annual Bonus Plan (the “Plan”) is adopted under the Tyra Biosciences, Inc. 2021 Incentive Award Plan (the “2021 Plan”) and is intended to provide an incentive for eligible employees of Tyra Biosciences, Inc.(the “Company”) to perform to the best of their abilities, to further the growth, development and financial success of the |
|
| March 22, 2023 |
Exhibit 10.21 FIRST AMENDMENT TO LEASE This First Amendment to Lease (this “Amendment”) is made and entered into as of May 16, 2022, by and between Fabric 2676 State Street, LLC, a California limited liability company (“Lessor”), and TYRA Biosciences, Inc., a Delaware corporation (“Lessee”). RECITALS A. Lessor and Lessee are parties to that certain AIR Standard Industrial/Commercial Multi-Tenant L |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2023 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40800 83-1476348 (State or other jurisdiction of incorporation) (Commissio |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2022 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40800 83-1476348 (State or other jurisdiction of incorporation) (Commissio |
|
| November 3, 2022 |
Exhibit 99.1 Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights -Pipeline on track; SURF301 study to be initiated; IND for TYRA-200 to be filed by year-end 2022- -Well-capitalized with cash and cash equivalents of $263.2 million as of Q3 2022- CARLSBAD, Calif., November 3, 2022 ? Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing pur |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2022 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 3, 2022 |
l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q l UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| October 11, 2022 |
Tyra Biosciences, Inc. 2656 State Street Carlsbad, CA 92008 Tyra Biosciences, Inc. 2656 State Street Carlsbad, CA 92008 October 11, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Tyra Biosciences, Inc. Registration Statement on Form S-3 File No. 333-267712 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under th |
|
| October 3, 2022 |
ATM Sales Agreement, dated October 3, 2022, by and between Virtu Americas LLC and the Registrant Exhibit 1.2 TYRA BIOSCIENCES, INC. Common Stock (par value $0.0001 per share) ATM Sales Agreement October 3, 2022 Virtu Americas LLC 1633 Broadway New York, NY 10019 Ladies and Gentlemen: Tyra Biosciences, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Virtu Americas LLC (the ?Agent?) as follows: 1. Issuance and Sale of Shares. The Company agrees that, |
|
| October 3, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 3, 2022 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40800 83-1476348 (State or other jurisdiction of incorporation) (Commission |
|
| October 3, 2022 |
Exhibit 4.4 TYRA BIOSCIENCES, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establishm |
|
| October 3, 2022 |
EX-FILING FEES 7 d370610dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Tyra Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggr |
|
| October 3, 2022 |
As filed with the Securities and Exchange Commission on October 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on October 3, 2022 Registration No. |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 04, 2022 Tyra Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40800 83-1476348 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 4, 2022 |
Exhibit 99.1 Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights -IND clearance received from FDA to proceed with SURF301 Study of TYRA-300- -Pipeline on track; IND for TYRA-200 to be filed in 2H 2022- -Well-capitalized with cash and cash equivalents of $275.1 million as of Q2 2022- CARLSBAD, Calif., August 4, 2022 ? Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision onco |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 4, 2022 |
Employment Letter Agreement, dated May 16, 2022, by and between Ali Fawaz and the Registrant TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into this 16th day of May, 2022 (the ?Effective Date?), by and between Tyra Biosciences, Inc., a Delaware corporation (the ?Company?) and Ali Fawaz (?Executive? and, together with the Company, the ?Parties?). Capitalized terms used herein and not otherwise defined shall have those meanings set forth |
|
| June 16, 2022 |
TYRA / Tyra Tech Inc / Boxer Capital, LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 16, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0. |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2022 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40800 83-1476348 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 5, 2022 |
Exhibit 99.1 Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights -Pipeline on-track; INDs to be filed for TYRA-300 and TYRA-200 in 2022- -Well-capitalized with cash and cash equivalents of $292.5 million as of Q1 2022- CARLSBAD, Calif., May 5, 2022 – Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcom |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2022 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40800 83-1476348 (State or other jurisdiction of incorporation or organization) |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| April 28, 2022 |
DEFA14A 1 d283123ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 24, 2022 |
EX-99.1 2 ex991to13g07422tyra03242022.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 24, 2022 with respect to the Common Stock, $0.0001 par value per share of Tyra Biosciences, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on beha |
|
| March 24, 2022 |
TYRA / Tyra Tech Inc / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Tyra Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 90240B106 (CUSIP Number) M |
|
| March 3, 2022 |
Exhibit 10.14 FIRST AMENDMENT TO LEASE This First Amendment to Lease (this ?Amendment?) is made and entered into as of March 2, 2022, by and between Fabric 2656 State, LLC, a California limited liability company (?Lessor?), and TYRA Biosciences, Inc., a Delaware corporation (?Lessee?). RECITALS A. Lessor and Lessee are parties to that certain AIR Standard Industrial/Commercial Multi-Lessee Lease - |
|
| March 3, 2022 |
Description of Registered Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Tyra Biosciences, Inc. (?we,? ?us? and ?our?) had one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. Description of Common Stock General The followin |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40800 TYRA BIOSCIENCE |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2022 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40800 83-1476348 (State or other jurisdiction of incorporation or organization |
|
| March 3, 2022 |
Exhibit 10.15 STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET 1. Basic Provisions (?Basic Provisions?). 1.1 Parties. This Lease (?Lease?), dated for reference purposes only March 2, 2022, is made by and between Fabric 2676 State Street, LLC, a California limited liability company (?Lessor?) and TYRA Biosciences, Inc., a Delaware corporation (?Lessee?), (collectively the ?Parties?, or indiv |
|
| March 3, 2022 |
Employment Letter Agreement, dated August 19, 2021, by and between John Healy and the Registrant Exhibit 10.12 TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of August 19, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and John Healy (“Executive” and, together with the Company, the “Parties”). This Agreement will be effective upon the consummation of the Company’s initial public offering (the “IPO |
|
| March 3, 2022 |
Exhibit 99.1 Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights -Pipeline on-track; INDs expected to be filed for TYRA-300 and TYRA-200 in 2022- -Strengthened organization with key appointment to clinical team- -Well-capitalized with cash and cash equivalents of $302.2 million as of YE 2021- CARLSBAD, Calif., March 3, 2022 ? Tyra Biosciences, Inc. (Nasdaq: |
|
| February 8, 2022 |
EX-99.24 2 d304292dex9924.htm EXHIBIT 24 Exhibit 24 2018 POWER OF ATTORNEY 1. Appointment, Powers and Revocation. KNOW ALL MEN BY THESE PRESENTS, that each undersigned, and if such undersigned is not a natural person, acting by and through one of its authorized representatives (each such undersigned person or entity, a “Grantor”), effective from the date set forth opposite the name of such Grantor |
|
| February 8, 2022 |
EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| February 8, 2022 |
TYRA / Tyra Tech Inc / Canaan XI L.P. - SC 13G Passive Investment SC 13G 1 d304292dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Tyra Biosciences, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 90240B 106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check th |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 3, 2021 |
Exhibit 99.1 Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights -Successful completion of upsized $198.7 million initial public offering; cash and cash equivalents of $312.8 million as of September 30, 2021- -Nominated 2nd product candidate for clinical development, TYRA-200 (FGFR2 inhibitor), from its SN?P platform- -Strengthened team with appointments of Esther van den |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2021 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40800 83-1476348 (State or other jurisdiction of incorporation or organizat |
|
| September 29, 2021 |
TCG Crossover Management, LLC - AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 90240B106 (CUSIP Number) September 15, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur |
|
| September 27, 2021 |
Exhibit 99.A EXHIBIT A JOINT FILING STATEMENT We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Tyra Biosciences, Inc. is filed on behalf of each of us. Dated: September 27, 2021 Nextech VI Oncology SCSp By: Nextech VI GP S.? r.l. its General Partner By: /s/ Dalia Bleyer Dalia Bleyer, Managing Member By: /s/ |
|
| September 27, 2021 |
RA CAPITAL MANAGEMENT, L.P. - SCHEDULE 13D SC 13D 1 tm2128529d1sc13d.htm SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 90240B106 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kol |
|
| September 27, 2021 |
Alta Partners NextGen Fund II Management, LLC - SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 90240B106 (CUSIP Number) Larry Randall Alta Partners NextGen Fund II Management, LLC 115 W Snow King Ave, Suite 101B Jackson, WY 83001 (415) 3 |
|
| September 27, 2021 |
NEXTECH VI ONCOLOGY SCSP - SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 90240B106 (CUSIP Number) September 17, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| September 24, 2021 |
SC 13D 1 d237021dsc13d.htm SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. )* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 90240B106 (CUSIP Number) David A. Brown Alston & Bird LLP 950 F Street, N.W. Washington, DC 20004-1404 202-23 |
|
| September 24, 2021 |
EX-99.1 2 d237021dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.0001 par value per share, of Tyra Biosciences, Inc. and further agree that |
|
| September 21, 2021 |
SC 13G 1 p921210sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tyra Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 90240B106 (CUSIP Number) September 15, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box |
|
| September 17, 2021 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TYRA BIOSCIENCES, INC. Tyra Biosciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is Tyra Biosciences, Inc. The Corporation was incorporated under the name Tyra Biosciences, Inc |
|
| September 17, 2021 |
8-K 1 d220261d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 17, 2021 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40800 83-1476348 (State or other jurisdiction of |
|
| September 17, 2021 |
Exhibit 3.2 Amended and Restated Bylaws of Tyra Biosciences, Inc. (a Delaware corporation) Table of Contents Page Article I—Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II—Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting 2 2.5 Notice of Nominations for Election to the Board |
|
| September 15, 2021 |
10,800,000 Shares Common Stock 424B4 1 d189651d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-258970 and 333-259531 PROSPECTUS 10,800,000 Shares Common Stock This is Tyra Biosciences, Inc.’s initial public offering. We are selling 10,800,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price per sha |
|
| September 15, 2021 |
As filed with the Securities and Exchange Commission on September 15, 2021 As filed with the Securities and Exchange Commission on September 15, 2021 Registration No. |
|
| September 14, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on September 14, 2021 Registration No. |
|
| September 14, 2021 |
As filed with the Securities and Exchange Commission on September 14, 2021 As filed with the Securities and Exchange Commission on September 14, 2021 Registration No. |
|
| September 10, 2021 |
September 10, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| September 10, 2021 |
Tyra Biosciences, Inc. 2656 State Street Carlsbad, CA 92008 Tyra Biosciences, Inc. 2656 State Street Carlsbad, CA 92008 September 10, 2021 VIA EDGAR Mr. Dillon Hagius Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Tyra Biosciences, Inc. Registration Statement on Form S-1 File No. 333-258970 Dear Mr. Hagius: Pursuant to Rule 461 of Regulation C of the General Rules |
|
| September 10, 2021 |
8-A12B 1 d213200d8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 83-1476348 (State of incorporation or organization) (I.R.S. Employer Identif |
|
| September 9, 2021 |
Tyra Biosciences, Inc. 2021 Employee Stock Purchase Plan EX-10.3 7 d189651dex103.htm EX-10.3 Exhibit 10.3 TYRA BIOSCIENCES, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: (i) the Section 423 Component and (ii) the Non-Section 423 Component. The Sect |
|
| September 9, 2021 |
Form of Underwriting Agreement Exhibit 1.1 Tyra Biosciences, Inc. (a Delaware corporation) [?] Shares of Common Stock UNDERWRITING AGREEMENT Dated: [?], 2021 Tyra Biosciences, Inc. (a Delaware corporation) [?] Shares of Common Stock UNDERWRITING AGREEMENT [?], 2021 BofA Securities, Inc. Jefferies LLC Cowen and Company, LLC as Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, New Yor |
|
| September 9, 2021 |
As filed with the Securities and Exchange Commission on September 9, 2021 S-1/A Table of Contents As filed with the Securities and Exchange Commission on September 9, 2021 Registration No. |
|
| September 9, 2021 |
Amended and Restated Certificate of Incorporation, as amended (currently in effect) EX-3.1 3 d189651dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TYRA BIOSCIENCES, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TYRA BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Tyra Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the Genera |
|
| September 9, 2021 |
Exhibit 4.2 Execution Version AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT CONTENTS Page 1.???Definitions 1 2.???Registration Rights 4 2.1??Demand Registration 4 2.2??Company Registration 6 2.3??Underwriting Requirements 6 2.4??Obligations of the Company 8 2.5??Furnish Information 9 2.6??Expenses of Registration 9 2.7??Delay of Registration 10 2.8??Indemnification 10 2.9??Reports Under Exchang |
|
| September 9, 2021 |
Non-Employee Director Compensation Program EX-10.4 8 d189651dex104.htm EX-10.4 Exhibit 10.4 TYRA BIOSCIENCES, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Tyra Biosciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Progra |
|
| September 9, 2021 |
EX-10.2 6 d189651dex102.htm EX-10.2 Exhibit 10.2 TYRA BIOSCIENCES, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities |
|
| August 20, 2021 |
Amended and Restated Certificate of Incorporation (currently in effect) Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TYRA BIOSCIENCES, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TYRA BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Tyra Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of |
|
| August 20, 2021 |
Exhibit 10.6 TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into this 6th day of January, 2020 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Dan Bensen (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and |
|
| August 20, 2021 |
12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh Düsseldorf San Diego August 20, 2021 Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai VIA EDGAR Houston Silicon Valley London Singapore Mr. Dillon Hagius Los Ange |
|
| August 20, 2021 |
Exhibit 10.19 STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET 1. Basic Provisions (?Basic Provisions?). 1.1 Parties. This Lease (?Lease?), dated for reference purposes only August 5, 2020, is made by and between Fabric 2656 State, LLC, a California limited liability company (?Lessor?) and TYRA Biosciences, Inc., a Delaware corporation (?Lessee?), (collectively the ?Parties?, or individuall |
|
| August 20, 2021 |
EX-10.16 20 d189651dex1016.htm EX-10.16 Exhibit 10.16 TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Hiroomi Tada (“Executive” and, together with the Company, the “Parties”). This Agreement will b |
|
| August 20, 2021 |
12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh Düsseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washington, D.C. Milan FOIA |
|
| August 20, 2021 |
EX-3.3 4 d189651dex33.htm EX-3.3 Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TYRA BIOSCIENCES, INC. Tyra Biosciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is Tyra Biosciences, Inc. The Corporation was incorporated und |
|
| August 20, 2021 |
Specimen stock certificate evidencing the shares of common stock EX-4.1 6 d189651dex41.htm EX-4.1 Exhibit 4.1 TYRA PO BOX 505006, Louisville, KY 40233-5006 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 CUSIP/IDENTIFIER XXXXXX XX X Holder ID XXXXXXXXXX Insurance Value 1,000,000.00 Number of Shares 123456 DTC 12345678 123456789012345 Certificate Numbers 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1 |
|
| August 20, 2021 |
Exhibit 3.2 BYLAWS OF TYRA BIOSCIENCES, INC. (A DELAWARE CORPORATION) Dated as of August 2, 2018 TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS’ ACTIONS 1 Section 1.1 Place of Meetings 1 Section 1.2 Annual Meeting 1 Section 1.3 Special Meetings 2 Section 1.4 Notice of Meetings 2 Section 1.5 Adjournment and Notice of Adjourned Meetings 2 Section 1.6 Record Date 2 Section 1.7 Quorum 3 Section 1.8 Vot |
|
| August 20, 2021 |
Employment Agreement, dated November 9, 2020, by and between Hiroomi Tada and the Registrant Exhibit 10.9 TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into this 9th day of November, 2020 (the ?Effective Date?), by and between Tyra Biosciences, Inc., a Delaware corporation (the ?Company?) and Hiroomi Tada (?Executive? and, together with the Company, the ?Parties?). Capitalized terms used herein and not otherwise defined shall have those |
|
| August 20, 2021 |
Employment Agreement, dated January 16, 2020, by and between Ronald Swanson and the Registrant Exhibit 10.8 TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into this 16th day of January, 2020 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Ronald Swanson (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and not otherwise defined shall have tho |
|
| August 20, 2021 |
Exhibit 10.17 TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the ?Agreement?) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the ?Company?) and Robert Hudkins (?Executive? and, together with the Company, the ?Parties?). This Agreement will be effective upon the consummation of t |
|
| August 20, 2021 |
Employment Agreement, dated April 16, 2021, by and between Esther van den Boom and the Registrant Exhibit 10.7 TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into this 16th day of April, 2021 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Esther van den Boom (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and not otherwise defined shall have |
|
| August 20, 2021 |
Exhibit 3.4 Amended and Restated Bylaws of Tyra Biosciences, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting 2 2.5 Notice of Nominations for Election to the B |
|
| August 20, 2021 |
Employment Agreement, dated January 1, 2021, by and between Robert Hudkins and the Registrant Exhibit 10.10 TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into this 1st day of January, 2021 (the ?Effective Date?), by and between Tyra Biosciences, Inc., a Delaware corporation (the ?Company?) and Robert Hudkins (?Executive? and, together with the Company, the ?Parties?). Capitalized terms used herein and not otherwise defined shall have tho |
|
| August 20, 2021 |
Exhibit 10.12 TYRA BIOSCIENCES, INC. SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Second Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Todd Harris (“Executive” and, together with the Company, the “Parties”). This Agreement will be effective upon the consum |
|
| August 20, 2021 |
Exhibit 10.15 TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the ?Agreement?) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the ?Company?) and Ronald Swanson (?Executive? and, together with the Company, the ?Parties?). This Agreement will be effective upon the consummation of t |
|
| August 20, 2021 |
Exhibit 4.2 Execution Version AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 4 2.2 Company Registration 6 2.3 Underwriting Requirements 6 2.4 Obligations of the Company 8 2.5 Furnish Information 9 2.6 Expenses of Registration 9 2.7 Delay of Registration 10 2.8 Indemnification 10 2.9 Reports Under Exchang |
|
| August 20, 2021 |
Employment Agreement, dated January 18, 2021, by and between Piyush Patel and the Registrant EX-10.11 15 d189651dex1011.htm EX-10.11 Exhibit 10.11 TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into this 18th day of January, 2021 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Piyush Patel (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein a |
|
| August 20, 2021 |
Form of Indemnification Agreement for Directors and Officers EX-10.20 24 d189651dex1020.htm EX-10.20 Exhibit 10.20 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”), and , [a member of the Board of Directors/ an officer] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company |
|
| August 20, 2021 |
Exhibit 10.13 TYRA BIOSCIENCES, INC. SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Second Amended and Restated Employment Agreement (the ?Agreement?) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the ?Company?) and Daniel Bensen (?Executive? and, together with the Company, the ?Parties?). This Agreement will be effective upon the cons |
|
| August 20, 2021 |
Power of Attorney (included on signature page) S-1 Table of Contents As filed with the Securities and Exchange Commission on August 20, 2021 Registration No. |
|
| August 20, 2021 |
EX-10.18 22 d189651dex1018.htm EX-10.18 Exhibit 10.18 TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Piyush Patel (“Executive” and, together with the Company, the “Parties”). This Agreement will b |
|
| August 20, 2021 |
EX-10.14 18 d189651dex1014.htm EX-10.14 Exhibit 10.14 TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into as of August 18, 2021, by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Esther van den Boom (“Executive” and, together with the Company, the “Parties”). This Agreement |
|
| August 20, 2021 |
Tyra Biosciences, Inc. 2020 Equity Incentive Plan and form of stock option agreement thereunder EX-10.1 8 d189651dex101.htm EX-10.1 Exhibit 10.1 TYRA BIOSCIENCES, INC. 2020 Equity Incentive Plan Adopted by the Board of Directors: January 6, 2020 Approved by the Stockholders: January 6, 2020 Termination Date: January 6, 2030 1. General. (a) Purpose. Tyra Biosciences, Inc. (the “Company”) hereby establishes this 2019 Equity Incentive Plan (the “Plan”). This Plan is intended: (i) to attract and |
|
| August 20, 2021 |
Exhibit 10.5 TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into this 6th day of January, 2020 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Todd Harris (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein an |
|
| July 2, 2021 |
TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT EX-10.7 5 filename5.htm Exhibit 10.7 TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into this 16th day of April, 2021 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Esther van den Boom (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and not other |
|
| July 2, 2021 |
TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.6 4 filename4.htm Exhibit 10.6 TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into this 6th day of January, 2020 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Dan Bensen (“Executive” and, together with the Company, the “Parties”). Capitaliz |
|
| July 2, 2021 |
TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.5 3 filename3.htm Exhibit 10.5 TYRA BIOSCIENCES, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into this 6th day of January, 2020 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Todd Harris (“Executive” and, together with the Company, the “Parties”). Capitali |
|
| July 2, 2021 |
TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT Exhibit 10.11 TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into this 18th day of January, 2021 (the ?Effective Date?), by and between Tyra Biosciences, Inc., a Delaware corporation (the ?Company?) and Piyush Patel (?Executive? and, together with the Company, the ?Parties?). Capitalized terms used herein and not otherwise defined shall have thos |
|
| July 2, 2021 |
DRS/A 1 filename1.htm Table of Contents As confidentially submitted to the Securities and Exchange Commission on July 2, 2021 as Amendment No. 1 to the draft Registration Statement. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 TYRA BIOSCIENCES, INC. (Exact name of registrant as specifi |
|
| July 2, 2021 |
EX-10.1 2 filename2.htm Exhibit 10.1 TYRA BIOSCIENCES, INC. 2020 Equity Incentive Plan Adopted by the Board of Directors: January 6, 2020 Approved by the Stockholders: January 6, 2020 Termination Date: January 6, 2030 1. General. (a) Purpose. Tyra Biosciences, Inc. (the “Company”) hereby establishes this 2019 Equity Incentive Plan (the “Plan”). This Plan is intended: (i) to attract and retain the |
|
| July 2, 2021 |
12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washington, D.C. Milan July |
|
| July 2, 2021 |
TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT EX-10.9 7 filename7.htm Exhibit 10.9 TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into this 9th day of November, 2020 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Hiroomi Tada (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and not otherwise |
|
| July 2, 2021 |
TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT EX-10.10 8 filename8.htm Exhibit 10.10 TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into this 1st day of January, 2021 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Robert Hudkins (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and not otherwi |
|
| July 2, 2021 |
TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT EX-10.8 6 filename6.htm Exhibit 10.8 TYRA BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into this 16th day of January, 2020 (the “Effective Date”), by and between Tyra Biosciences, Inc., a Delaware corporation (the “Company”) and Ronald Swanson (“Executive” and, together with the Company, the “Parties”). Capitalized terms used herein and not otherwis |
|
| May 28, 2021 |
As confidentially submitted to the Securities and Exchange Commission on May 28, 2021. DRS 1 filename1.htm Table of Contents As confidentially submitted to the Securities and Exchange Commission on May 28, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 TYRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 2834 83-1476348 (State or oth |
|
| May 28, 2021 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TYRA BIOSCIENCES, INC. EX-3.1 2 filename2.htm Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TYRA BIOSCIENCES, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TYRA BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Tyra Biosciences, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporat |
|
| May 28, 2021 |
BYLAWS TYRA BIOSCIENCES, INC. (A DELAWARE CORPORATION) Dated as of August 2, 2018 EX-3.2 3 filename3.htm Exhibit 3.2 BYLAWS OF TYRA BIOSCIENCES, INC. (A DELAWARE CORPORATION) Dated as of August 2, 2018 TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS’ ACTIONS 1 Section 1.1 Place of Meetings 1 Section 1.2 Annual Meeting 1 Section 1.3 Special Meetings 2 Section 1.4 Notice of Meetings 2 Section 1.5 Adjournment and Notice of Adjourned Meetings 2 Section 1.6 Record Date 2 Section 1.7 Q |
